For the quarter ending 2026-03-31, NAGE had $1,761K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 6,318 | 4,132 | 4,578 | 8,672 |
| Depreciation of leasehold improvements and equipment | 116 | 139 | 157 | 316 |
| Amortization of intangibles | 175 | 60 | 38 | 75 |
| Noncash lease expense | 173 | 169 | 164 | 332 |
| Gain from sale of operating segment | 4,784 | - | - | - |
| Share-based compensation expense | 1,716 | 1,748 | 1,756 | 2,563 |
| Loss on disposal of leasehold improvements and equipment | 0 | 0 | 0 | -4 |
| (recovery of) / allowance for credit losses | 85 | 27 | -12 | -1,232 |
| Reversal of previously accrued royalties and license maintenance fees | - | 0 | - | - |
| Gain on settlement of royalty obligation | - | 1,983 | - | - |
| Interest accretion on deferred consideration | 114 | 38 | - | - |
| Non-cash financing costs | -12 | -18 | -15 | -26 |
| Trade receivables | 3,412 | 1,262 | -1,162 | 656 |
| Inventories | 3,573 | 2,036 | 4,385 | 5,214 |
| Implementation costs for cloud computing arrangement | 30 | 0 | 0 | 66 |
| Prepaid expenses and other assets | 169 | -746 | -87 | -288 |
| Accounts payable | 2,481 | -1,946 | -938 | 5,154 |
| Accrued expenses | -101 | 958 | 1,319 | -436 |
| Deferred revenue | -102 | 0 | 0 | 95 |
| Customer deposits and other | -13 | 107 | -16 | -308 |
| Operating lease liabilities | -241 | -236 | -233 | -480 |
| Deferred consideration liability | 41 | - | - | - |
| Net cash (used in) / provided by operating activities | -1,194 | 679 | 3,692 | 9,133 |
| Purchases of leasehold improvements and equipment | 61 | 101 | 24 | 167 |
| Proceeds from sale of operating segment | 5,800 | - | - | - |
| Proceeds from the sale of leasehold improvements and equipment, net | - | 0 | 0 | - |
| Transaction costs from sale of operating segment | 494 | - | - | - |
| Net cash (used in) / provided by investing activities | 5,245 | -101 | -24 | -167 |
| Payment of deferred consideration | 47 | - | - | - |
| Proceeds from exercise of stock options | 111 | 228 | 152 | 6,866 |
| Repurchase of common stock | 2,354 | 251 | - | - |
| Payment of debt issuance costs | 0 | 55 | 0 | 12 |
| Principal payments on finance leases | 0 | 2 | 4 | 6 |
| Net cash (used in) / provided by financing activities | -2,290 | -80 | 148 | 6,848 |
| Net increase in cash and cash equivalents | 1,761 | 498 | 3,816 | 15,814 |
| Cash and cash equivalents at beginning of period | - | - | 44,660 | - |
| Cash and cash equivalents at end of period | - | - | 64,290 | - |
Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. (NAGE)